MHRA grants bluebird 'innovation passport' for sickle cell t...

bluebird bio's sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an 'innovation passport' introduced in the UK earlier this year to speed up NHS access to promisi

ASH: CRISPR, Vertex' CTX001 hits the mark in red cell disord...

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta thalassaemia and sickle cell disease in an early-stage tr

2nd Gene Therapy for Blood Disorders

Gene Therapy for Blood Disorders Digital Summit

LentiGlobin gene therapy for sickle cell on course for filin...

FDA approves Global Blood Therapeutics' sickle cell pill

Global Blood Therapeutics has seen its sickle cell disease drug approved by the FDA, promising to be the first treatment targeting the root cause of the condition.

CRISPR trials yield encouraging data in blood disorders